Pharmaceutical Companies

As part of the transaction, Actio Biosciences will establish a new privately held company dedicated to developing treatments for genetic rare neurological diseases.

The approval from the Medicines and Healthcare products Regulatory Agency (MHRA) marks another milestone in the rapidly growing market for oral weight-loss medicines.

The agreement covers joint clinical studies that will combine BeOne’s oncology pipeline with four clinical-stage RAS(ON) inhibitors developed by Revolution Medicines: daraxonrasib, zoldonrasib, elironrasib and RMC-5127.

The study is designed to provide confirmatory evidence for lacutamab in two CTCL subtypes, Sézary syndrome and mycosis fungoides, potentially supporting full regulatory approval.

The centerpiece of the deal is gildeuretinol, formerly known as ALK-001, a once-daily oral therapy under development for Stargardt disease, a rare inherited retinal disorder.

The approval expands Orzeyful’s commercial reach following its authorization in China in July 2026, marking another milestone in Takeda’s global launch strategy.

Under the agreement, Ono will work with Mediar to identify potential treatments using the biotechnology company’s fibrosis-focused discovery platform and expertise in myofibroblast biology and fibrosis-related pathways.

Under the four-year agreement, Novartis India had granted Dr Reddy’s an exclusive and non-transferable right to promote, distribute and sell certain products in the Indian market.

The companies will combine Evotec’s screening technologies, compound libraries and AI-enabled discovery platform with Odyssey’s expertise in the biology of autoimmune and inflammatory diseases.